Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients :: A Cohort Study

Aitana Ayet-Roger; Lorena Joga-Elvira; Assumpta Caixàs i Pedragós; Raquel Corripio

doi:10.3390/jcm11061592

Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients : A Cohort Study

Aitana Ayet-Roger, Lorena Joga-Elvira, Assumpta Caixàs i Pedragós, Raquel Corripio

Research output: Contribution to journal › Article › Research › peer-review

11 Citations (Scopus)

Abstract

Background: Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.

Original language	English
Journal	Journal of Clinical Medicine
Volume	11
DOIs	https://doi.org/10.3390/jcm11061592
Publication status	Published - 2022

Keywords

Prader-Willi Syndrome
Growth hormone treatment
Cognition
Adaptive behavior

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jcm11061592

https://ddd.uab.cat/record/258158

Cite this

@article{3eaecad316e348a6a8886b30798a41d1,

title = "Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients :: A Cohort Study",

abstract = "Background: Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.",

keywords = "Prader-Willi Syndrome, Growth hormone treatment, Cognition, Adaptive behavior",

author = "Aitana Ayet-Roger and Lorena Joga-Elvira and {Caix{\`a}s i Pedrag{\'o}s}, Assumpta and Raquel Corripio",

year = "2022",

doi = "10.3390/jcm11061592",

language = "English",

volume = "11",

}

TY - JOUR

T1 - Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients :

T2 - A Cohort Study

AU - Ayet-Roger, Aitana

AU - Joga-Elvira, Lorena

AU - Caixàs i Pedragós, Assumpta

AU - Corripio, Raquel

PY - 2022

Y1 - 2022

N2 - Background: Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.

AB - Background: Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.

KW - Prader-Willi Syndrome

KW - Growth hormone treatment

KW - Cognition

KW - Adaptive behavior

U2 - 10.3390/jcm11061592

DO - 10.3390/jcm11061592

M3 - Article

C2 - 35329918

SN - 2077-0383

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine